Please login to the form below

Not currently logged in
Email:
Password:

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.

The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder. 

Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.

6th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Taylor James

Taylor James is a creative production studio working at the forefront of content production. Headquartered in London, we deliver award...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....